Home/Pipeline/Undisclosed Parkinson's Program

Undisclosed Parkinson's Program

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Sinopia Biosciences

About Sinopia Biosciences

Sinopia Biosciences is a private, pre-clinical stage biotech harnessing AI/ML and a proprietary multi-omics platform to redefine drug discovery for complex neurodegenerative diseases. The company's core technology, the LEADS® platform, utilizes advanced metabolomics and deep learning foundation models to decode disease biology and identify novel small molecule therapeutics, beginning with a program for Parkinson's disease. Led by a team with strong computational and biological expertise, Sinopia aims to accelerate the discovery of breakthrough treatments by moving beyond traditional target-centric approaches to restore system-wide cellular health.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active